CONTEXT: The PTH/PTHrP receptor type 1 (PTHR1) has a key role in endochondral ossification, which is emphasized by diseases resulting from mutations in the PTHR1 gene. Among these diseases is Blomstrand osteochondrodysplasia (BOCD). OBJECTIVE: BOCD can be divided into two types, depending on the severity of the skeletal abnormalities. The molecular basis for this heterogenic presentation is unknown. DESIGN AND PATIENTS: We performed mutation analysis in two families with type I and in three families with the less severe form of BOCD type II. RESULTS: In one of the type I BOCD cases, a homozygous nonsense mutation (R104X) was found, resulting in a truncated PTHR1. In the second type I BOCD case, no mutation was found. A homozygous nucleotide change (intron M4+27C>T) was demonstrated in one of the type II BOCD cases creating a novel splice site. In dermal fibroblasts of the patient, this novel splice site was preferentially used, resulting in an aberrant transcript. The wild-type transcript remained, however, present, albeit at low levels. In the other two families with type II BOCD, a previously identified homozygous missense mutation (P132L) was found. Functional analysis demonstrated that the P132L mutant had low residual activity. CONCLUSIONS: In combination with data presented in literature, we conclude that type I BOCD is caused by a complete inactivation of the PTHR1, whereas low levels of residual activity due to a near complete inactivation of the PTHR1 result in the relatively milder presentation of type II BOCD.
CONTEXT: The PTH/PTHrP receptor type 1 (PTHR1) has a key role in endochondral ossification, which is emphasized by diseases resulting from mutations in the PTHR1 gene. Among these diseases is Blomstrand osteochondrodysplasia (BOCD). OBJECTIVE: BOCD can be divided into two types, depending on the severity of the skeletal abnormalities. The molecular basis for this heterogenic presentation is unknown. DESIGN AND PATIENTS: We performed mutation analysis in two families with type I and in three families with the less severe form of BOCD type II. RESULTS: In one of the type I BOCD cases, a homozygous nonsense mutation (R104X) was found, resulting in a truncated PTHR1. In the second type I BOCD case, no mutation was found. A homozygous nucleotide change (intron M4+27C>T) was demonstrated in one of the type II BOCD cases creating a novel splice site. In dermal fibroblasts of the patient, this novel splice site was preferentially used, resulting in an aberrant transcript. The wild-type transcript remained, however, present, albeit at low levels. In the other two families with type II BOCD, a previously identified homozygous missense mutation (P132L) was found. Functional analysis demonstrated that the P132L mutant had low residual activity. CONCLUSIONS: In combination with data presented in literature, we conclude that type I BOCD is caused by a complete inactivation of the PTHR1, whereas low levels of residual activity due to a near complete inactivation of the PTHR1 result in the relatively milder presentation of type II BOCD.
Authors: Helmut Roth; Lars G Fritsche; Christoph Meier; Peter Pilz; Martin Eigenthaler; Philipp Meyer-Marcotty; Angelika Stellzig-Eisenhauer; Peter Proff; Cláudia M Kanno; Bernhard Hf Weber Journal: Clin Oral Investig Date: 2013-06-15 Impact factor: 3.573
Authors: Eva Decker; Angelika Stellzig-Eisenhauer; Britta S Fiebig; Christiane Rau; Wolfram Kress; Kathrin Saar; Franz Rüschendorf; Norbert Hubner; Tiemo Grimm; Bernhard H F Weber Journal: Am J Hum Genet Date: 2008-12 Impact factor: 11.025
Authors: Andrew Arnold; Elaine Dennison; Christopher S Kovacs; Michael Mannstadt; René Rizzoli; Maria Luisa Brandi; Bart Clarke; Rajesh V Thakker Journal: Nat Rev Endocrinol Date: 2021-03-16 Impact factor: 43.330
Authors: Hariharan Subramanian; Frank Döring; Sina Kollert; Natalia Rukoyatkina; Julia Sturm; Stepan Gambaryan; Angelika Stellzig-Eisenhauer; Philipp Meyer-Marcotty; Martin Eigenthaler; Erhard Wischmeyer Journal: PLoS One Date: 2016-11-29 Impact factor: 3.240